Ureter Cancer - Pipeline Review, H1 2020 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Ureter Cancer - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Ureter Cancer - Pipeline Review, H1 2020, provides an overview of the Ureter Cancer (Oncology) pipeline landscape.

Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Ureter Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ureter Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ureter Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 9 and 6 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively.

Ureter Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Ureter Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Ureter Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Ureter Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Ureter Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Ureter Cancer (Oncology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Ureter Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Ureter Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Ureter Cancer - Overview
• Ureter Cancer - Therapeutics Development
• Ureter Cancer - Therapeutics Assessment
• Ureter Cancer - Companies Involved in Therapeutics Development
• Ureter Cancer - Drug Profiles
• Ureter Cancer - Dormant Projects
• Ureter Cancer - Product Development Milestones
• Appendix

Companies Mentioned

• Altor Bioscience LLC
• Aravive Inc
• Astellas Pharma Inc
• AstraZeneca Plc
• Dragonfly Therapeutics Inc
• Eisai Co Ltd
• Exelixis Inc
• Genentech Inc
• GlaxoSmithKline Plc
• Kyowa Kirin Co Ltd
• MacroGenics Inc
• MedPacto Inc
• Merck & Co Inc
• Merck KGaA
• Pfizer Inc
• Shionogi & Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jr2de1